DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novartis Pharma AG

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

106 Comunicados de prensa

Ver todos los comunicados de prensa
12/06/2026
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmacéutica
Anuncios breves
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmacéutica
Anuncios breves
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmacéutica
Anuncios breves
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
03/06/2026
Farmacéutica
Anuncios breves
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
01/06/2026
Farmacéutica
Anuncios breves
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
31/05/2026
Farmacéutica
Anuncios breves
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
30/05/2026
Farmacéutica
Anuncios breves
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
25/05/2026
Farmacéutica
Anuncios breves
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
20/05/2026
Farmacéutica
Anuncios breves
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0